Adiponectin is associated with cardiovascular disease in male renal transplant recipients: Baseline results from the LANDMARK 2 study

BMC Nephrology

Volumn 10, Issue 1, 2009, Pages

  Kaisar, Mohd O ^a,b   Armstrong, Kirsty ^a,b   Hawley, Carmel ^a   Campbell, Scott ^a   Mudge, David ^a   Johnson, David W ^a,b   Prins, John B ^b   Isbel, Nicole M ^a,b  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CALCINEURIN INHIBITOR; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN; PREDNISOLONE; TACROLIMUS; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; ANAMNESIS; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG USE; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE TOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LABORATORY TEST; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PROTEIN BLOOD LEVEL; RISK FACTOR; RISK MANAGEMENT; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO; AGED; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SEXUAL DEVELOPMENT;

ADIPONECTIN; ADULT; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; SEX CHARACTERISTICS;

EID: 70449372606     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-10-29     Document Type: Article

References (31)

1. Cardiovascular disease posttransplant. PT Pham PC Pham GM Donovitch, Semin Nephrol 2007 27 4 430 44 10.1016/j.semnephrol.2007.03.005 17616275
2. Adiponectin: linking the metabolic syndrome to its cardiovascular consequences. KR Rabin Y Kamari I Avni E Grossman Y Sharabi, Expert Rev Cardiovasc Ther 2005 3 3 465 471 10.1586/14779072.3.3.465 15889974
3. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. K Hara M Horikoshi T Yamauchi H Yago O Miyazaki H Ebinuma Y Imai R Nagai T Kadowaki, Diabetes Care 2006 29 6 1357 1362 10.2337/dc05-1801 16732021
4. Adiponectin - a key adipokine in the metabolic syndrome. JP Whitehead AA Richards IJ Hickman GA Macdonald JB Prins, Diabetes Obes Metab 2006 8 3 264 280 10.1111/j.1463-1326.2005.00510.x 16634986
5. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. K Hotta T Funahashi Y Arita M Takahashi M Matsuda Y Okamoto H Iwahashi H Kuriyama N Ouchi K Maeda M Nishida S Kihara N Sakai T Nakajima K Hasegawa M Muraguchi Y Ohmoto T Nakamura S Yamashita T Hanafusa Y Matsuzawa, Arterioscler Thromb Vasc Biol 2000 20 6 1595 1599 10845877
6. Association of hypoadiponectinemia with smoking habit in men. Y Iwashima T Katsuya K Ishikawa I Kida M Ohishi T Horio N Ouchi K Ohashi S Kihara T Funahashi H Rakugi T Ogihara, Hypertension 2005 45 6 1094 1100 10.1161/01.HYP.0000169444.05588.4c 15897361
7. Decreased plasma concentration of a novel anti-inflammatory protein adiponectin in hypertensive men with coronary artery disease. Z Dzielĩska A Januszewicz A Wiecek M Demkow M Makowiecka-Ciela A Prejbisz J Kadziela R Mielniczuk E Florczak J Janas M Januszewicz W Ruzyo, Thromb Res 2003 110 5-6 365 369 10.1016/j.thromres.2003.08.004 14592564
8. Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. C Zoccali F Mallamaci V Panuccio G Tripepi S Cutrupi S Parlongo F Catalano S Tanaka N Ouchi S Kihara T Funahashi Y Matsuzawa, Kidney Int Suppl 2003 84 98 102 10.1046/j.1523-1755.63.s84.49.x 12694320
9. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. C Zoccali F Mallamaci G Tripepi FA Benedetto S Cutrupi S Parlongo LS Malatino G Bonanno G Seminara F Rapisarda P Fatuzzo M Buemi G Nicocia S Tanaka N Ouchi S Kihara T Funahashi Y Matsuzawa, J Am Soc Nephrol 2002 13 1 134 141 11752030 (Pubitemid 34042020)
10. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. B Becker F Kronenberg JT Kielstein H Haller C Morath E Ritz D Fliser MMKD Study Group, J Am Soc Nephrol 2005 16 4 1091 1098 10.1681/ASN.2004090742 15743998
11. Adiponectin and renal function, and implication as a risk of cardiovascular disease. Y Iwashima T Horio M Kumada Y Suzuki S Kihara H Rakugi Y Kawano T Funahashi T Ogihara, Am J Cardiol 2006 98 12 1603 1608 10.1016/j.amjcard.2006.07.039 17145218
12. Adiponectin and risk of new-onset diabetes mellitus after kidney transplantation. B Bayes R Lauzurica ML Granada A Serra J Bonet N Fontsere I Salinas R Romero, Transplantation 2004 78 1 26 30 10.1097/01.TP.0000132561. 48217.B1 15257035
13. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus Geneva, World Health Organization 1999
14. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 106 25 3143 3421 12485966
15. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults - The Evidence Report. National Institutes of Health. Obes Res 1998 6 Suppl 2 51S 209S 9813653
16. Adiponectin and mortality in patients with chronic kidney disease. V Menon L Li X Wang T Greene V Balakrishnan M Madero AA Pereira GJ Beck JW Kusek AJ Collins AS Levey MJ Sarnak, J Am Soc Nephrol 2006 17 9 2599 2606 10.1681/ASN.2006040331 16885405 (Pubitemid 44300977)
17. Adiponectin and renal disease progression: another epidemiologic conundrum? C Zoccali F Mallamaci, Kidney Int 2007 71 12 1195 1197 10.1038/sj.ki.5002319 17554349
18. Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. Y Fu N Luo RL Klein WT Garvey, J Lipid Res 2005 46 1369 1379 10.1194/jlr.M400373-JLR200 15834118
19. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. M Cnop PJ Havel KM Utzschneider DB Carr MK Sinha EJ Boyko BM Retzlaff RH Knopp JD Brunzell SE Kahn, Diabetologia 2003 46 4 459 469 12687327
20. Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. CS Mantzoros T Li JE Manson JB Meigs FB Hu, J Clin Endocrinol Metab 2005 90 8 4542 4548 10.1210/jc.2005-0372 15914524
21. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. N Ouchi S Kihara T Funahashi T Nakamura M Nishida M Kumada Y Okamoto K Ohashi H Nagaretani K Kishida H Nishizawa N Maeda H Kobayashi H Hiraoka Y Matsuzawa, Circulation 2003 107 671 674 10.1161/01.CIR.0000055188. 83694.B3 12578865
22. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. PA Kern GB Di Gregorio T Lu N Rassouli G Ranganathan, Diabetes 2003 52 1779 1785 10.2337/diabetes.52.7.1779 12829646
23. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. J Krakoff T Funahashi CD Stehouwer CG Schalkwijk S Tanaka Y Matsuzawa S Kobes PA Tataranni RL Hanson WC Knowler RS Lindsay, Diabetes Care 2003 26 1745 1751 10.2337/diacare.26.6.1745 12766104
24. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. N Ouchi S Kihara Y Arita Y Okamoto K Maeda H Kuriyama K Hotta M Nishida M Takahashi M Muraguchi Y Ohmoto T Nakamura S Yamashita T Funahashi Y Matsuzawa, Circulation 2000 102 1296 1301 10982546
25. Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. Y Takemura N Ouchi R Shibata T Aprahamian MT Kirber RS Summer S Kihara K Walsh, J Clin Invest 2007 117 375 386 10.1172/JCI29709 17256056
26. Adipocyte-derived plasma protein, adiponectin, acts as a platelet-derived growth-factor-BB-binding protein and regulates growth factor-induced common post-receptor signal in vascular smooth muscle cell. Y Arita S Kihara N Ouchi, et al. Circulation 2002 105 2893 2898 10.1161/01.CIR.0000018622.84402.FF 12070119
27. Adiponectin stimulates nitric oxide production in vascular endothelial cells. H Chen M Montagnani T Funahashi I Shimomura MJ Quon, J Biol Chem 2003 278 45021 45026 10.1074/jbc.M307878200 12944390
28. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. M Kumada S Kihara N Ouchi, et al. Circulation 2004 109 2046 2049 10.1161/01.CIR.0000127953.98131.ED 15096450
29. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. K Koh M Quon S Han, et al. Hypertension 2005 45 1088 1093 10.1161/01.HYP.0000166722.91714.ba 15883229
30. Blockade of the renin-angiotensin system increases plasma adiponectin concentration in type 2 diabetic patients with proteinuria. M Yenicesu MI Yilmaz K Caglar, et al. Nephron Clin Pract 2005 99 115 121 10.1159/000083929 (Pubitemid 40522793)
31. The effect of thiazolidinedione on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. JG Yu S Javorschi AL Hevener YT Kruszynska RA Norman M Sinha JM Olefsky, Diabetes 2002 51 2968 2974 10.2337/diabetes.51.10. 2968 12351435